GlyphAgo Phase 1 PK Shows 6.8x Bioavailability, 10x Lower Variability
SPTX sits 22% above its 52-week low of $14.85.
Summary
Seaport Therapeutics released detailed Phase 1 pharmacokinetic data for GlyphAgo (SPT-320), its oral agomelatine prodrug for generalized anxiety disorder. The data show a 6.8-fold increase in bioavailability versus unmodified agomelatine, roughly 10-fold lower PK variability, no food effect, no OCP interaction, and no accumulation over 7 days. These results de-risk the program by supporting lower, more predictable dosing and fewer drug-drug interactions. The Phase 2a trial in GAD is already underway, with a Phase 2/3 planned for the first half of 2027. This follows the first-patient dosing announcement on October 7 and the positive Phase 1 driving simulation results from September 9. The next major efficacy readout is not expected until 2027–2028.
At the time of this announcement, SPTX was trading at $18.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $958.7M. The 52-week trading range was $14.85 to $28.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.